US WorldMeds' Opioid Withdrawal Drug Lofexidine Heads To US FDA Panel

Sponsor seeks a novel claim for facilitating completion of opioid discontinuation treatment, but agency's external experts will weigh in on evidentiary threshold for such an indication; FDA staff give mixed review to patient-reported outcomes instrument used as primary endpoint in two pivotal trials.

An ampoule Opioid next to it is a note written in English Opioid epidemic. All around, many tablets and syringes are scattered.

A US FDA advisory committee will weigh the efficacy and safety of US WorldMeds LLC's Lucemyra (lofexidine) for managing symptoms of acute opioid withdrawal, as well as the adequacy of the evidence to support a novel claim – facilitation of completion of opioid discontinuation treatment.

The Psychopharmacologic Drugs Advisory Committee will meet March 27 to consider a dual indication for lofexidine, a new molecular entity...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers